VANCOUVER, Oct. 4 /CNW/ - Ondine Biopharma Corporation (TSX: OBP;
AIM: OBP) today announced results from a prospective, randomized, controlled,
blinded clinical trial of its Periowave(TM) Photodynamic Disinfection (PDD)
System for the treatment of periodontal diseases. Results showed significant
improvement in pocket depth, clinical attachment level and bleeding on probing
when compared to the gold standard of scaling and root planing (SRP).
